CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
Xuejiao Liu(Xuzhou Medical College), Rutong Yu(Xuzhou Medical College)
Cited by 80
Related Papers
Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy
|International Journal of Nanomedicine|2017|95
<p>Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma</p>
|International Journal of Nanomedicine|2020|56
MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways
|Frontiers in Oncology|2021|46
RETRACTED ARTICLE: GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death
|Cell Death and Disease|2021|42